These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12199669)

  • 21. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
    Franchini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s33-8. PubMed ID: 19105508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease.
    Cumming AM; Fildes S; Cumming IR; Wensley RT; Redding OM; Burn AM
    Br J Haematol; 1990 Jun; 75(2):234-9. PubMed ID: 2115374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/factor VIII concentrate.
    Iorio A; James P; Ma A; Srivastava A
    J Thromb Haemost; 2024 Oct; 22(10):2739-2744. PubMed ID: 38950781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
    Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).
    Thompson AR; Gill JC; Ewenstein BM; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2004 Jan; 10(1):42-51. PubMed ID: 14962219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.
    Goudemand J; Scharrer I; Berntorp E; Lee CA; Borel-Derlon A; Stieltjes N; Caron C; Scherrmann JM; Bridey F; Tellier Z; Federici AB; Mannucci PM
    J Thromb Haemost; 2005 Oct; 3(10):2219-27. PubMed ID: 16194199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
    Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
    Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
    Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
    Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
    Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ; Kershaw G; McLachlan AJ; Lloyd J
    Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
    Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
    Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.